AMES, IA--(Marketwired - May 6, 2013) - NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapiesto improve treatment options for patients with cancer, today reported consolidated financial results for the first quarter of 2013.

"We are looking forward to completing patient accrual for our IMPRESS trial of algenpantucel-L for surgically resected pancreatic cancer. It was also encouraging to see additional clinical trials of both our HyperAcute and IDO product candidates advancing this past quarter," commented Dr. Charles Link, Chairman and Chief Executive Officer of NewLink."In addition, NewLink presented preclinical results for our second IDO pathway inhibitor drug candidate, NLG919, at the American Association for Cancer Research annual meeting. Based on these data, we plan to initiate a clinical trial with NLG919 later this year, further expanding our clinical development programs."

First Quarter and Recent Accomplishments

Pipeline:

Corporate:

Upcoming Activities

NewLink expects to present at the following conferences:

First Quarter 2013 Financial Results

Financial Guidance

NewLink expects to end 2013 with about $40 million in cash, cash equivalents and marketable securities.

Excerpt from:
NewLink Genetics Corporation Reports First Quarter 2013 Financial Results

Comments are closed.